Results 21 to 30 of about 18,181 (226)

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product

open access: yesOpen Access Rheumatology: Research and Reviews, 2017
Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O’Sullivan, Ann Maria Curran, John J Carey Department of Rheumatology, Galway University Hospitals, Galway ...
Abdalla A   +8 more
doaj   +1 more source

Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data [PDF]

open access: yes, 2017
In 2006, the European Medicines Agency (EMA) approved Omnitrope(®) as a biosimilar recombinant human growth hormone (rhGH), on the basis of comparable quality, safety, and efficacy to the reference medicine (Genotropin(®), Pfizer).
Zabransky, Markus   +11 more
core   +1 more source

Etanercept biosimilars [PDF]

open access: yesRheumatology International, 2014
Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept patent set to expire in the EU in 2015, a number of etanercept copies have reached the production phase and are undergoing clinical trials, with the promise of being ...
Azevedo, Valderilio F.   +4 more
openaire   +2 more sources

Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation [PDF]

open access: yesТерапевтический архив, 2019
Real - life data on the effectiveness and safety of biosimilar and biologic drugs licensed for treatment of inflammatory bowel diseases (IBD) is lacking. Aim.
O V Knyazev   +7 more
doaj   +1 more source

The Future of Biosimilar Insulins [PDF]

open access: yes, 2016
IN BRIEF Biosimilar insulins are available in many countries and will be made available in the United States in the near future. Some concerns associated with biosimilar insulins include potential differences in the efficacy and safety between a ...
Kim, Anne Park, Bindler, Ross Jason
core   +1 more source

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends

open access: yesFrontiers in Pharmacology, 2023
Background: Factors like the number of biosimilar competitors and competitive pricing strategies from originator companies may influence price competition and biosimilar uptake.Objective: The aim of this study was to analyze multiple facets of biosimilar
Elif Car   +5 more
doaj   +1 more source

What do oncologists need to know about biosimilar products?

open access: yesChinese Journal of Cancer, 2016
Many biologic products have improved the outcomes of cancer patients, but the costs can substantially burden healthcare systems. Biosimilar products can potentially reduce drug costs and increase patient access to beneficial treatments.
Linda K. S. Leung   +3 more
doaj   +1 more source

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices

open access: yesACR Open Rheumatology, 2020
Objective It is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Nick Bansback   +8 more
doaj   +1 more source

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study

open access: yesFrontiers in Oncology, 2023
BackgroundBevacizumab has played an important role in the systemic treatment of patients with advanced non-small-cell lung cancer (NSCLC) without gene mutation.
Zhiting Zhao   +11 more
doaj   +1 more source

Financial Analysis of Biosimilar Development Candidates: A Case Study on the US Biosimilar Business

open access: yes, 2016
This case study investigates the US biosimilar business and the approach that should be implemented when financially analyzing biosimilar development candidates.
Gutierrez, Bryan J.
core   +5 more sources

Home - About - Disclaimer - Privacy